Elena Fea

Cuneo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Chemotherapy at the end-of-life: the reasons why it is not a good parameter for evaluating clinical choices in oncology

Chemotherapy at the end-of-life: the reasons why it is not a good parameter for evaluating clinical choices in oncology

Journal: Recenti progressi in medicina

Published: November 02, 2025

Predictors of duration of hospital stay for cancer patients admitted due to medical causes: A quality-improvement evaluation.

Predictors of duration of hospital stay for cancer patients admitted due to medical causes: A quality-improvement evaluation.

Journal: Tumori

Published: October 18, 2025

Emergency Care for Patients with Cancer on Immune Checkpoint Inhibitors: A Retrospective Analysis of Immune-Related Adverse Events.

Emergency Care for Patients with Cancer on Immune Checkpoint Inhibitors: A Retrospective Analysis of Immune-Related Adverse Events.

Journal: The Journal of emergency medicine

Published: June 01, 2025

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.

Journal: BMC cancer

Published: May 06, 2024

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.

Journal: BMC cancer

Published: December 19, 2023

Patients with cancer and hospital admissions: disease trajectory and strategic choices.

Patients with cancer and hospital admissions: disease trajectory and strategic choices.

Journal: BMJ supportive & palliative care

Published: August 25, 2023

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.

Journal: Clinical genitourinary cancer

Published: July 08, 2023

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review.

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review.

Journal: European journal of case reports in internal medicine

Published: May 13, 2021

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.

Journal: World journal of clinical oncology

Published: February 27, 2021

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.

Journal: Vaccines

Published: February 23, 2021

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2021

Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy.

Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy.

Journal: Tumori

Published: July 25, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026